Clinical Trials Logo

Mantle Cell Lymphoma (MCL) clinical trials

View clinical trials related to Mantle Cell Lymphoma (MCL).

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06464861 Not yet recruiting - Clinical trials for Mantle Cell Lymphoma (MCL)

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma

CD19-CARNK/T
Start date: June 10, 2024
Phase: Phase 1
Study type: Interventional

To study the safety and efficacy of cord blood-derived CD19 CAR-NK cells sequential with 7x19 CAR-T in relapse / refractory B cell lymphoma

NCT ID: NCT04767308 Not yet recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Start date: March 2021
Phase: Early Phase 1
Study type: Interventional

Current treatments for relapsed/refractory hematopoietic malignancies such as B-cell lymphomas (BCLs) and peripheral T-cell lymphomas (PTCLs) are far from satisfactory. CD5 is widely expressed in multiple subtypes of BCLs and PTCLs but rarely found in normal tissues except certain types of lymphocytes. Chimeric antigen receptor (CAR) T cells against CD5 offer another potential therapeutic option for patients with relapsed/refractory CD5 positive hematopoietic malignancies. In the current study, the safety and efficacy of a novel CAR T cell therapy, termed CT125A cells, are evaluated in patients with relapsed/refractory CD5+ hematopoietic malignancies. The endogenous CD5 in CT125A cells is knocked out via CRISPR/Cas9 genome editing technology to prevent fratricide during CAR T cells manufacturing.